These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 30993097)

  • 81. Activating mutation (V617F) in the tyrosine kinase JAK2 is absent in locally-confined or castration-resistant prostate cancer.
    Gu L; Zhu XH; Visakorpi T; Alanen K; Mirtti T; Edmonston TB; Nevalainen MT
    Anal Cell Pathol (Amst); 2010; 33(2):55-9. PubMed ID: 20966544
    [TBL] [Abstract][Full Text] [Related]  

  • 82. The polycythemia vera-associated Jak2 V617F mutant induces tumorigenesis in nude mice.
    Abe M; Funakoshi-Tago M; Tago K; Kamishimoto J; Aizu-Yokota E; Sonoda Y; Kasahara T
    Int Immunopharmacol; 2009 Jul; 9(7-8):870-7. PubMed ID: 19327411
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Dnmt3a is downregulated by Stat5a and mediates G0/G1 arrest by suppressing the miR-17-5p/Cdkn1a axis in Jak2
    Zhou J; Guo C; Wu H; Li B; Zhou LL; Liang AB; Fu JF
    BMC Cancer; 2021 Nov; 21(1):1213. PubMed ID: 34773997
    [TBL] [Abstract][Full Text] [Related]  

  • 84. The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3.
    Hookham MB; Elliott J; Suessmuth Y; Staerk J; Ward AC; Vainchenker W; Percy MJ; McMullin MF; Constantinescu SN; Johnston JA
    Blood; 2007 Jun; 109(11):4924-9. PubMed ID: 17317861
    [TBL] [Abstract][Full Text] [Related]  

  • 85. In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele.
    Gaikwad A; Nussenzveig R; Liu E; Gottshalk S; Chang K; Prchal JT
    Exp Hematol; 2007 Apr; 35(4):587-95. PubMed ID: 17379069
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2
    Hu M; Xu C; Yang C; Zuo H; Chen C; Zhang D; Shi G; Wang W; Shi J; Zhang T
    J Exp Clin Cancer Res; 2019 Feb; 38(1):49. PubMed ID: 30717771
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Activation of JAK2-V617F by components of heterodimeric cytokine receptors.
    Pradhan A; Lambert QT; Griner LN; Reuther GW
    J Biol Chem; 2010 May; 285(22):16651-63. PubMed ID: 20363735
    [TBL] [Abstract][Full Text] [Related]  

  • 88. The role of serum erythropoietin level and JAK2 V617F allele burden in the diagnosis of polycythaemia vera.
    Ancochea A; Alvarez-Larrán A; Morales-Indiano C; García-Pallarols F; Martínez-Avilés L; Angona A; Senín A; Bellosillo B; Besses C
    Br J Haematol; 2014 Nov; 167(3):411-7. PubMed ID: 25040297
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Polycythemia vera is not initiated by JAK2V617F mutation.
    Nussenzveig RH; Swierczek SI; Jelinek J; Gaikwad A; Liu E; Verstovsek S; Prchal JF; Prchal JT
    Exp Hematol; 2007 Jan; 35(1):32-8. PubMed ID: 17198871
    [TBL] [Abstract][Full Text] [Related]  

  • 90. [Analysis of CALR, JAK2 and MPL gene mutations in BCR-ABL negative myeloproliferative neoplasms].
    Ouyang Y; Qiao C; Wang J; Xiao L; Zhang S
    Zhonghua Yi Xue Za Zhi; 2015 May; 95(18):1369-73. PubMed ID: 26178351
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation.
    Hexner E; Roboz G; Hoffman R; Luger S; Mascarenhas J; Carroll M; Clementi R; Bensen-Kennedy D; Moliterno A
    Br J Haematol; 2014 Jan; 164(1):83-93. PubMed ID: 24903629
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Is the JAK2 V617F mutation a hallmark for different forms of thrombosis?
    Zerjavic K; Zagradisnik B; Stangler Herodez S; Lokar L; Glaser Krasevac M; Kokalj Vokac N
    Acta Haematol; 2010; 124(1):49-56. PubMed ID: 20616539
    [TBL] [Abstract][Full Text] [Related]  

  • 93. JAK-2 V617F Mutational Analysis in Primary Idiopathic Myelofibrosis: Experience from Southern Pakistan.
    Sultan S; Irfan SM
    Asian Pac J Cancer Prev; 2015; 16(17):7889-92. PubMed ID: 26625816
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Long non-coding RNA RP11-480I12.5 promotes cervical carcinoma progression by regulating the Wnt/β-catenin signaling pathway.
    Zhang L; Li Y; Sona L
    Oncol Lett; 2020 Jan; 19(1):469-475. PubMed ID: 31897160
    [TBL] [Abstract][Full Text] [Related]  

  • 95. "
    Langabeer SE
    J Cancer Prev; 2019 Mar; 24(1):59-60. PubMed ID: 30993097
    [No Abstract]   [Full Text] [Related]  

  • 96. Response to Letter to Editor "
    Sohrabi A
    J Cancer Prev; 2019 Mar; 24(1):61-62. PubMed ID: 30993098
    [No Abstract]   [Full Text] [Related]  

  • 97. Characterization of JAK2 V617F (1849 G > T) Mutation in Cervical Cancer Related to Human Papillomavirus and Sexually Transmitted Infections.
    Abdolmaleki M; Sohrabi A
    J Cancer Prev; 2018 Jun; 23(2):82-86. PubMed ID: 30003068
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population.
    Nielsen C; Birgens HS; Nordestgaard BG; Bojesen SE
    Br J Haematol; 2013 Jan; 160(1):70-9. PubMed ID: 23116358
    [TBL] [Abstract][Full Text] [Related]  

  • 99. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S; Michiels JJ
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [TBL] [Abstract][Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.